Live
An agreement has been signed by Themis Medicare with Nevakar LLC for further developing, manufacturing and marketing latter’s injectable products in the US and some other select countries.
Themis Medicare has said in a BSE filing that “Under the agreement Themis will develop a selected number of innovative, differentiated injectable products that will be further developed, manufacture and commercialised by Nevakar in the US and select global markets.”
It further said that the New Jersey based speciality pharmaceutical firm Navakar has expertise in commercialising pharma products in the US as well as global markets for many years.
